Natalizumab reduces serum pro-angiogenic activity in MS patients
- 105 Downloads
Angiogenesis has been implicated in the pathobiology of multiple sclerosis (MS). Osteopontin exerts a pro-angiogenetic effect and is increased in body fluid of MS patients. To evaluate the effect of 1 year natalizumab treatment on serum pro-angiogenic activity and on plasma osteopontin levels in relapsing (RR) MS patients. Ten RRMS patients scheduled for natalizumab treatment were enrolled and evaluated at baseline and after 1-year natalizumab treatment. Pro-angiogenic activity was assessed by a chick embryo chorioallantoic membrane assay (CAM), osteopontin levels were evaluated by an enzyme-linked immunosorbent assay. Plasma and serum samples of 10 treatment-naïve RRMS and 10 healthy controls (HCs) were used as controls of baseline evaluations. Both treatment-naïve and natalizumab scheduled RRMS patients had higher baseline vessel density (22.0 ± 3.9 and 22.5 ± 2.6, p < 0.0001) and higher osteopontin levels (65.7 ± 24.3 ng/ml and 65.9 ± 16.6 ng/ml, p = 0.019 and p = 0.029, respectively) than HCs (9.0 ± 2.2; 48.5 ± 7.8 ng/ml, respectively). Baseline osteopontin levels and vessel density were significantly correlated (rs = 0.373, p = 0.043). After 1 year of treatment, the number of vessels and the osteopontin levels, were significantly reduced (11.9 ± 2.1, p < 0.005; 49.3 ± 20.0 ng/ml, p = 0.028). Our results suggest that natalizumab could exert its anti-inflammatory properties also by inhibiting the angiogenetic mechanisms in RRMS patients.
KeywordsMultiple sclerosis Angiogenesis Osteopontin Natalizumab Chick embryo chorioallantoic membrane assay Enzyme-linked immunosorbent assay
Compliance with ethical standards
Conflict of interest statement
PI has served on scientific advisory boards for Biogen Idec, and has received funding for travel and/or speaker honoraria from Sanofi-Aventis, Biogen Idec, Teva and Novartis. MT has received honoraria for consultancy or speaking from Biogen, Sanofi-Aventis, Merck Serono, and Bayer-Schering and research grants from Merck Serono, Biogen and Novartis. DR declares no conflict of interest.
The study was approved by the Ethics Committee of the University of Bari Medical School.
Written informed consent was obtained by all patients before the start of natalizumab (NTZ).
- 3.Kirk J, Plumb J, Mirakhur M, McQuaid S (2003) Tight junctional abnormality in multiple sclerosis white matter affects all calibers of vessel and is associated with blood–brain barrier leakage and active demyelination. J Pathol 201(2):319–327. https://doi.org/10.1002/path.1434 CrossRefPubMedGoogle Scholar
- 4.van Horssen J, Bö L, Vos CM, Virtanen I, de Vries HE (2005) Basement membrane proteins in multiple sclerosis-associated inflammatory cuffs: potential role in influx and transport of leukocytes. J Neuropathol Exp Neurol 64(8):722–729. https://doi.org/10.1097/01.jnen.0000173894.09553.13 CrossRefPubMedGoogle Scholar
- 6.Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan YC, Olander JV, Connolly DT, Stern D (1990) Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172(6):1535–1545. https://doi.org/10.1084/jem.172.6.1535 CrossRefPubMedGoogle Scholar
- 12.Iaffaldano P, Ruggieri M, Viterbo RG, Mastrapasqua M, Trojano M (2014) The improvement of cognitive functions is associated with a decrease of plasma osteopontin levels in natalizumab treated relapsing multiple sclerosis. Brain Behav Immun 35:176–181. https://doi.org/10.1016/j.bbi.2013.08.009 CrossRefPubMedGoogle Scholar
- 13.Chabas D, Baranzini SE, Mitchell D, Bernard CC, Rittling SR, Denhardt DT, Sobel RA, Lock C, Karpuj M, Pedotti R, Heller R, Oksenberg JR, Steinman L (2001) The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294(5547):1731–1735. https://doi.org/10.1126/science.1062960 CrossRefPubMedGoogle Scholar
- 14.Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW, AFFIRM Investigators (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899–910. https://doi.org/10.1056/NEJMoa044397 CrossRefPubMedGoogle Scholar
- 15.Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 354(9):911–923. https://doi.org/10.1056/NEJMoa044396 CrossRefPubMedGoogle Scholar
- 16.Iaffaldano P, Viterbo RG, Paolicelli D, Lucchese G, Portaccio E, Goretti B, Direnzo V, D'Onghia M, Zoccolella S, Amato MP, Trojano M (2012) Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. PLoS One 7(4):e35843. https://doi.org/10.1371/journal.pone.0035843 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, Piehl F, Sellebjerg F, Olsson T (2009) The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol 16(4):528–536. https://doi.org/10.1111/j.1468-1331.2009.02532.x CrossRefPubMedGoogle Scholar
- 18.O'Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N (2011) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76(22):1858–1865. https://doi.org/10.1212/WNL.0b013e31821e7c8a CrossRefPubMedGoogle Scholar
- 21.Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore GB, Marrosu MG, Amato MP, Bertolotto A, Bergamaschi R, Granella F, Coniglio G, Tedeschi G, Sola P, Lus G, Ferrò MT, Iuliano G, Corea F, Protti A, Cavalla P, Guareschi A, Rodegher M, Paolicelli D, Tortorella C, Lepore V, Prosperini L, Saccà F, Baroncini D, Comi G, and Maria Trojano on behalf of the Italian iMed-Web database (2015) Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain 138(pt 11):3275–3286. https://doi.org/10.1093/brain/awv260
- 23.Podar K, Zimmerhackl A, Fulciniti M, Tonon G, Hainz U, Tai YT, Vallet S, Halama N, Jäger D, Olson DL, Sattler M, Chauhan D, Anderson KC (2011) The selective adhesion molecule inhibitor natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br J Haematol 155(4):438–448. https://doi.org/10.1111/j.1365-2141.2011.08864.x CrossRefPubMedGoogle Scholar
- 26.Proescholdt MA, Jacobson S, Tresser N, Oldfield EH, Merrill MJ (2002) Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. J Neuropathol Exp Neurol 61(10):914–925. https://doi.org/10.1093/jnen/61.10.914 CrossRefPubMedGoogle Scholar
- 29.Sinclair C, Mirakhur M, Kirk J, Farrell M, McQuaid S (2005) Up-regulation of osteopontin and alphaBeta-crystallin in the normal-appearing white matter of multiple sclerosis: an immunohistochemical study utilizing tissue microarrays. Neuropathol Appl Neurobiol 31(3):292–230. https://doi.org/10.1111/j.1365-2990.2004.00638.x CrossRefPubMedGoogle Scholar
- 32.Li XD, Chen J, Ruan CC, Zhu DL, Gao PJ (2012) Vascular endothelial growth factor-induced osteopontin extression emdiates vasculr inflammation and neointima formation via Flt-1 in adventitial fibroblasts. Arterioscler Thromb Vasc Biol 32(9):2250–2258. https://doi.org/10.1161/ATVBAHA.112.255216 CrossRefPubMedGoogle Scholar